JP2004510752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004510752A5 JP2004510752A5 JP2002532304A JP2002532304A JP2004510752A5 JP 2004510752 A5 JP2004510752 A5 JP 2004510752A5 JP 2002532304 A JP2002532304 A JP 2002532304A JP 2002532304 A JP2002532304 A JP 2002532304A JP 2004510752 A5 JP2004510752 A5 JP 2004510752A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antibody
- monoclonal antibody
- fragment
- malignant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 98
- 239000012634 fragment Substances 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 67
- 230000003211 malignant effect Effects 0.000 claims description 34
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 29
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 108010063916 CD40 Antigens Proteins 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000017604 Hodgkin disease Diseases 0.000 claims description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 8
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 208000025113 myeloid leukemia Diseases 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000004797 therapeutic response Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 4
- 230000005593 dissociations Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 description 53
- 230000001154 acute effect Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23755600P | 2000-10-02 | 2000-10-02 | |
| PCT/US2001/030963 WO2002028481A2 (en) | 2000-10-02 | 2001-10-02 | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007305086A Division JP2008074870A (ja) | 2000-10-02 | 2007-11-26 | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| JP2008220544A Division JP4838831B2 (ja) | 2000-10-02 | 2008-08-28 | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004510752A JP2004510752A (ja) | 2004-04-08 |
| JP2004510752A5 true JP2004510752A5 (enExample) | 2005-12-22 |
| JP4202127B2 JP4202127B2 (ja) | 2008-12-24 |
Family
ID=22894238
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002532486A Expired - Lifetime JP4271440B2 (ja) | 2000-10-02 | 2001-10-02 | ヒト抗ｃｄ４０抗体 |
| JP2002532304A Expired - Fee Related JP4202127B2 (ja) | 2000-10-02 | 2001-10-02 | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| JP2007299859A Pending JP2008156339A (ja) | 2000-10-02 | 2007-11-19 | ヒト抗ｃｄ４０抗体 |
| JP2007305086A Pending JP2008074870A (ja) | 2000-10-02 | 2007-11-26 | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| JP2008220544A Expired - Fee Related JP4838831B2 (ja) | 2000-10-02 | 2008-08-28 | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| JP2009143746A Pending JP2009201523A (ja) | 2000-10-02 | 2009-06-16 | ヒト抗ｃｄ４０抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002532486A Expired - Lifetime JP4271440B2 (ja) | 2000-10-02 | 2001-10-02 | ヒト抗ｃｄ４０抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007299859A Pending JP2008156339A (ja) | 2000-10-02 | 2007-11-19 | ヒト抗ｃｄ４０抗体 |
| JP2007305086A Pending JP2008074870A (ja) | 2000-10-02 | 2007-11-26 | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| JP2008220544A Expired - Fee Related JP4838831B2 (ja) | 2000-10-02 | 2008-08-28 | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| JP2009143746A Pending JP2009201523A (ja) | 2000-10-02 | 2009-06-16 | ヒト抗ｃｄ４０抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7288252B2 (enExample) |
| EP (3) | EP1326896B1 (enExample) |
| JP (6) | JP4271440B2 (enExample) |
| AT (3) | ATE541860T1 (enExample) |
| AU (4) | AU2001296547A1 (enExample) |
| CA (2) | CA2424749A1 (enExample) |
| DE (2) | DE60119945T2 (enExample) |
| ES (1) | ES2357051T3 (enExample) |
| PT (1) | PT1326896E (enExample) |
| WO (4) | WO2002028480A2 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| AU2001296547A1 (en) | 2000-10-02 | 2002-04-15 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
| EP2301575A1 (en) | 2003-11-04 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for solid tumors expressing the CD40 cell-surface antigen |
| WO2005044304A2 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| DE602004028272D1 (de) * | 2003-11-04 | 2010-09-02 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom |
| WO2005044306A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
| PL1684869T3 (pl) * | 2003-11-04 | 2011-12-30 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia nowotworów wywodzących się z limfocytów B |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| EP2316859A1 (en) | 2005-04-09 | 2011-05-04 | Fusion Antibodies Limited | Cathepsin S antibody |
| EP1894012A2 (en) * | 2005-05-18 | 2008-03-05 | Novartis AG | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| PL1889065T3 (pl) | 2005-05-18 | 2013-12-31 | Novartis Ag | Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny |
| CA2628105A1 (en) | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
| US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
| US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
| US7993648B2 (en) | 2006-05-03 | 2011-08-09 | The Regents of the Universitry of Colorado | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| AU2008260498B2 (en) * | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
| US20110002934A1 (en) * | 2007-11-09 | 2011-01-06 | Novartis Ag | Uses of anti-cd40 antibodies |
| EP2245065A1 (en) * | 2008-01-23 | 2010-11-03 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| CN103415534A (zh) | 2009-03-10 | 2013-11-27 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
| CN105884903B (zh) | 2009-03-10 | 2019-12-06 | 贝勒研究院 | 靶向抗原呈递细胞的疫苗 |
| ES2584956T3 (es) * | 2009-03-10 | 2016-09-30 | Baylor Research Institute | Anticuerpos anti-CD40 y usos de los mismos |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| TR201909840T4 (tr) | 2011-03-11 | 2019-07-22 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antikorları ve kullanımları. |
| AR085573A1 (es) | 2011-03-25 | 2013-10-09 | Baylor Res Inst | Composiciones y metodos de inmunizacion contra el virus de la hepatitis c |
| EP3372616A1 (en) * | 2011-04-21 | 2018-09-12 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize cd40 |
| EP2780372B1 (en) * | 2011-11-17 | 2019-01-02 | Jung, Gundram | Bi-specific antibodies for medical use |
| JP2016011258A (ja) * | 2012-10-26 | 2016-01-21 | 株式会社ペルセウスプロテオミクス | 抗ヒトｃｄ４０モノクローナル抗体及びその利用 |
| EP2920210B1 (en) | 2012-11-19 | 2017-08-30 | Baliopharm AG | Recombinant bispecific antibody binding to cd20 and cd95 |
| CN106103483A (zh) | 2014-01-13 | 2016-11-09 | 贝勒研究院 | 抗hpv和hpv相关的疾病的新疫苗 |
| WO2015134988A1 (en) | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| KR20240073140A (ko) | 2014-10-29 | 2024-05-24 | 씨젠 인크. | 비-푸코실화된 항-cd40 항체의 용량 및 투여 |
| US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| JP6518917B2 (ja) | 2015-05-29 | 2019-05-29 | アッヴィ・インコーポレイテッド | 抗ｃｄ４０抗体およびその使用 |
| JP6976931B2 (ja) | 2015-09-04 | 2021-12-08 | プリマトープ・セラピューティクス・インコーポレイテッド | ヒト化抗ｃｄ４０抗体及びその使用 |
| KR20180053738A (ko) * | 2015-09-30 | 2018-05-23 | 얀센 바이오테크 인코포레이티드 | 인간 cd40과 특이적으로 결합하는 길항적 항체 및 사용 방법 |
| US11365256B2 (en) | 2016-06-08 | 2022-06-21 | Xencor, Inc. | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US11091557B2 (en) | 2016-07-14 | 2021-08-17 | Genmab A/S | Methods of producing multispecific antibodies against CD40 and CD137 |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| BR112019025048A2 (pt) | 2017-06-01 | 2020-06-30 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos |
| CN108503708B (zh) * | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd47抗体及其用途 |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| US20230023414A1 (en) | 2018-11-19 | 2023-01-26 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| MX2021006360A (es) | 2018-11-30 | 2021-08-11 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica de anticuerpo cd40 y uso de la misma. |
| MX2021005823A (es) | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo. |
| EP3917960A1 (en) * | 2019-02-01 | 2021-12-08 | LAVA Therapeutics N.V. | Novel cd40-binding antibodies |
| NL2022494B1 (en) * | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| IL293450A (en) | 2019-12-03 | 2022-07-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| WO2022189498A1 (en) | 2021-03-09 | 2022-09-15 | Genmab A/S | Multispecific binding agents against cd40 and cd137 in therapy |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4327257A1 (en) | 2021-05-07 | 2024-02-28 | Redkik Oy | Risk probability assessment for cargo shipment operations and methods of use thereof |
| CN117295764A (zh) * | 2021-06-28 | 2023-12-26 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及医药用途 |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| JP2024531480A (ja) | 2021-08-26 | 2024-08-29 | デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド | ステロイド化合物及びそのコンジュゲート |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20250249278A1 (en) | 2022-04-14 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| JP2025541738A (ja) | 2022-12-01 | 2025-12-23 | ビオンテック・ソシエタス・エウロパエア | 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US142358A (en) * | 1873-09-02 | Improvement in the purification of illuminating-gas | ||
| US59427A (en) * | 1866-11-06 | Improvement in fences | ||
| US4355023A (en) | 1980-09-30 | 1982-10-19 | The Massachusetts General Hospital | Antibody fragment compositions and process |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4689299A (en) | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4727018A (en) | 1984-05-18 | 1988-02-23 | Eichner Ronald D | Immunoregulation of transplantable tissue |
| US5068223A (en) | 1985-09-09 | 1991-11-26 | Board Of Regents, University Of Texas System | Hydrophobic peptide esters and amides |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US4923872A (en) | 1986-08-26 | 1990-05-08 | Warner-Lambert Co. | Analogues of pyrrolo[3,2d]pyrimidin-4-ones |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| ATE68347T1 (de) * | 1987-01-17 | 1991-11-15 | Asta Pharma Ag | Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika. |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| EP0434879A1 (en) | 1989-12-14 | 1991-07-03 | Schering-Plough | Method of making factor dependent human B cell lines |
| WO1992000092A1 (en) | 1990-07-02 | 1992-01-09 | Bristol-Myers Squibb Company | Ligand for cd28 receptor on b cells and methods |
| EP0897983B1 (en) | 1991-10-25 | 2003-05-07 | Immunex Corporation | Antibody against CD40-L |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
| AU4554493A (en) | 1992-07-07 | 1994-01-31 | Eleanor N. Fish | Interferon receptor binding peptides |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| EP0651797B1 (en) * | 1992-07-09 | 2004-01-28 | Chiron Corporation | A method for generation of antibodies to cell surface molecules |
| AU5098493A (en) | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| JP3675819B2 (ja) | 1993-10-01 | 2005-07-27 | イミュネックス・コーポレーション | Ｃｄ４０に対する抗体 |
| DE69433820T2 (de) * | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| EP0823941A4 (en) * | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| EP1221973B1 (en) * | 1999-10-04 | 2007-05-30 | Novartis Vaccines and Diagnostics, Inc. | CD40 antagonist for treating psoriasis |
| US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| WO2001034649A2 (en) | 1999-11-09 | 2001-05-17 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
| WO2001083755A2 (en) * | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| AU2001296547A1 (en) * | 2000-10-02 | 2002-04-15 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
-
2001
- 2001-10-02 AU AU2001296547A patent/AU2001296547A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030961 patent/WO2002028480A2/en not_active Ceased
- 2001-10-02 EP EP01979395A patent/EP1326896B1/en not_active Expired - Lifetime
- 2001-10-02 DE DE60119945T patent/DE60119945T2/de not_active Expired - Lifetime
- 2001-10-02 AU AU2001296507A patent/AU2001296507A1/en not_active Abandoned
- 2001-10-02 PT PT01979395T patent/PT1326896E/pt unknown
- 2001-10-02 AU AU2001296545A patent/AU2001296545A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030859 patent/WO2002028905A2/en not_active Ceased
- 2001-10-02 ES ES01979395T patent/ES2357051T3/es not_active Expired - Lifetime
- 2001-10-02 AT AT06005656T patent/ATE541860T1/de active
- 2001-10-02 WO PCT/US2001/030963 patent/WO2002028481A2/en not_active Ceased
- 2001-10-02 EP EP01977428A patent/EP1322383B9/en not_active Expired - Lifetime
- 2001-10-02 DE DE60143535T patent/DE60143535D1/de not_active Expired - Lifetime
- 2001-10-02 CA CA002424749A patent/CA2424749A1/en not_active Abandoned
- 2001-10-02 AU AU2002211366A patent/AU2002211366A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030857 patent/WO2002028904A2/en not_active Ceased
- 2001-10-02 CA CA002424296A patent/CA2424296A1/en not_active Abandoned
- 2001-10-02 JP JP2002532486A patent/JP4271440B2/ja not_active Expired - Lifetime
- 2001-10-02 AT AT01979395T patent/ATE489403T1/de active
- 2001-10-02 EP EP06005656A patent/EP1717251B1/en not_active Expired - Lifetime
- 2001-10-02 JP JP2002532304A patent/JP4202127B2/ja not_active Expired - Fee Related
- 2001-10-02 US US10/380,223 patent/US7288252B2/en not_active Expired - Fee Related
- 2001-10-02 AT AT01977428T patent/ATE327004T1/de not_active IP Right Cessation
-
2007
- 2007-08-31 US US11/849,107 patent/US7445780B2/en not_active Expired - Fee Related
- 2007-11-19 JP JP2007299859A patent/JP2008156339A/ja active Pending
- 2007-11-26 JP JP2007305086A patent/JP2008074870A/ja active Pending
-
2008
- 2008-08-28 JP JP2008220544A patent/JP4838831B2/ja not_active Expired - Fee Related
- 2008-10-06 US US12/246,029 patent/US7611708B2/en not_active Expired - Fee Related
-
2009
- 2009-06-16 JP JP2009143746A patent/JP2009201523A/ja active Pending
- 2009-09-28 US US12/568,373 patent/US7820170B2/en not_active Expired - Fee Related
-
2010
- 2010-09-27 US US12/891,415 patent/US8088383B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004510752A5 (enExample) | ||
| JP2004517611A5 (enExample) | ||
| CA2261630C (en) | Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease | |
| Williams et al. | Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. | |
| JP2007513073A5 (enExample) | ||
| JP2007512243A5 (enExample) | ||
| WO2005044855A3 (en) | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma | |
| JP2008529497A5 (enExample) | ||
| JP2005506035A5 (enExample) | ||
| US20110020332A1 (en) | Prevention of tumors with monoclonal antibodies against neu | |
| JP2006528626A5 (enExample) | ||
| WO1994022478A1 (en) | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU) | |
| JP2007533330A5 (enExample) | ||
| WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| RU2011137369A (ru) | Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента | |
| JP2014501729A5 (enExample) | ||
| RU2006103854A (ru) | Антитела к рецептору инсулиноподобного фактора роста i и их применение | |
| JPWO2019228266A5 (enExample) | ||
| RU2014122189A (ru) | Способы снижения частоты и тяжести острых приступов астмы | |
| JP2007526908A5 (enExample) | ||
| JP2008514730A5 (enExample) | ||
| CA2370814A1 (en) | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit | |
| JP2005505256A5 (enExample) | ||
| RU2020133229A (ru) | Антитела к klk5 и способы применения | |
| JP2019535797A5 (enExample) |